03.02.09
Sinovac Biotech Ltd. has received GMP certification from the China’s State Food and Drug Administration (SFDA) for its filling and packaging production facility. The certificate of compliance was issued following a site inspection and has a five-year term.
The GMP certification provides for an overall annual production capacity of 20 million doses, with the capability to produce as many as 40 million doses. This certification allows Sinovac to meet current and potential production increases for products including Healive, Bilive and Anflu. The production plant also has the capabilities to fill and package Panflu, the company's pandemic flu vaccine.
Weidong Yin, chairman, president and chief executive officer, commented, “The receipt of the GMP certification and the operation of the state-of-the-art filling and packaging facility provide the foundation for the further development of Sinovac. We are well positioned to increase output to meet increasing market demand and ultimately achieve sales growth. More importantly, the expanded production capacity should enable Sinovac to supply greater amount of vaccines, which is in line with our mission to eliminate human diseases.”